Cigna (CI) Reports Q4 Earnings: What Key Metrics Have to Say

30.01.25 15:30 Uhr

Werte in diesem Artikel
Aktien

270,80 EUR -20,70 EUR -7,10%

Indizes

6.040,5 PKT -30,6 PKT -0,50%

Cigna (CI) reported $65.68 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 28.4%. EPS of $6.64 for the same period compares to $6.79 a year ago.The reported revenue represents a surprise of +3.85% over the Zacks Consensus Estimate of $63.25 billion. With the consensus EPS estimate being $7.83, the EPS surprise was -15.20%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Cigna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Medical Care Ratio - Cigna Healthcare: 87.9% versus 84.5% estimated by eight analysts on average. Medical Customers - Total: 19.15 million compared to the 19.17 million average estimate based on five analysts. Total Medical Customers - Medicare Part D: 2.57 million versus the three-analyst average estimate of 2.56 million. Medical Customers - U.S. Healthcare administrative services: 13.65 million versus the three-analyst average estimate of 13.63 million. Revenues- Fees and Other: $3.93 billion versus the six-analyst average estimate of $3.73 billion. The reported number represents a year-over-year change of +29%. Revenues- Premiums: $11.50 billion versus the six-analyst average estimate of $11.45 billion. The reported number represents a year-over-year change of +2.9%. Revenues- Pharmacy: $49.94 billion versus the six-analyst average estimate of $48.20 billion. The reported number represents a year-over-year change of +36.4%. Revenues- Evernorth Health Services: $53.74 billion compared to the $51.10 billion average estimate based on six analysts. The reported number represents a change of +32.6% year over year. Revenues- Cigna Healthcare- Premiums: $11.38 billion versus the six-analyst average estimate of $11.27 billion. The reported number represents a year-over-year change of +2.5%. Revenues- Net investment income: $277 million versus $254.43 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -4.5% change. Revenues- Cigna Healthcare: $13.30 billion versus $13.37 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +2.5% change. Revenues- Evernorth Health Services- Pharmacy: $50.75 billion versus $48.74 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +34.4% change. View all Key Company Metrics for Cigna here>>>Shares of Cigna have returned +9.8% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cigna Group (CI): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Q4

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Q4

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu The Cigna Group Registered Shs

Wer­bung

Analysen zu The Cigna Group Registered Shs

DatumRatingAnalyst
20.07.2018Express Scripts NeutralRobert W. Baird & Co. Incorporated
08.03.2018Express Scripts Equal WeightBarclays Capital
08.03.2018Cigna OverweightBarclays Capital
31.01.2018Express Scripts OutperformRBC Capital Markets
15.12.2017Express Scripts OutperformRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
08.03.2018Cigna OverweightBarclays Capital
31.01.2018Express Scripts OutperformRBC Capital Markets
15.12.2017Express Scripts OutperformRobert W. Baird & Co. Incorporated
14.12.2017Express Scripts BuyMaxim Group
04.12.2017Express Scripts BuyDeutsche Bank AG
DatumRatingAnalyst
20.07.2018Express Scripts NeutralRobert W. Baird & Co. Incorporated
08.03.2018Express Scripts Equal WeightBarclays Capital
19.09.2017Express Scripts Sector PerformRBC Capital Markets
21.07.2017Express Scripts HoldNeedham & Company, LLC
26.04.2017Express Scripts HoldEdward Jones
DatumRatingAnalyst
22.02.2016Express Scripts SellDeutsche Bank AG
13.01.2009CIGNA sellCitigroup Corp.
07.11.2007CIGNA underweightLehman Brothers Inc.
02.11.2006Update CIGNA Corp.: UnderweightLehman Brothers

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für The Cigna Group Registered Shs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"